Virginia Bio

In @CBS6, CEO John Newby highlights how the amended #SB271 could limit patient access to prescribed treatments and harm the Commonwealth’s growing life science sector. Price controls, whether at the state or federal level, are never the answer. bit.ly/4boIgbq

In @8NEWS, CEO John Newby highlights how a #PDAB would undermine continued life sciences growth here in the Commonwealth. There is no evidence that a #PDAB is effective at lowering patients' costs. Watch now ➡ wric.com/news/politics/…

The Virginia General Assembly is putting patients first by moving forward to study the #340B program. Before expanding this little-known program, it’s critical that our lawmakers understand who it really benefits. More in @RTDNews from @MedicareMeddler: bit.ly/4uoPZis

In @WDBJ7, CEO John Newby highlights how a #PDAB could make it harder for VA patients to access lifesaving care and limit investment in our growing biotech industry. SB 271 is not the answer for Virginia patients. See more ➡ bit.ly/4lkzGz3

Early bird savings for BIO International Convention 2026 are ending soon! Register by March 26 to save up to $550. This is the lowest registration rate for 2026, and prices increase after March 26. 🔗 Secure your spot and savings now: bit.ly/4llSNbG

Less than 2 months until THRiVE 2026! Thank you to our amazing sponsors: Catalyst, VEDP, GMU, VIPC, VWR, DPR, Greenberg Traurig, ATCC, and Goochland County Economic Development. Register now: bit.ly/4s1RgLb #THRiVE2026 #ThankYouSponsors #LifeSciences #VirginiaBio

In a new @VirginiaMercury article, CEO John Newby explains why a VA stakeholder working group on the #340B program will help ensure 340B is serving vulnerable patients as intended. Keep reading: bit.ly/4skj64z

1 in 10 Americans lives with a rare disease — and most still have no approved treatment. This #RareDiseaseDay, Virginia Bio stands with those who depend on medical innovation. Let’s protect the research ecosystem making breakthroughs possible. rarediseaseday.org

⏰ Last chance! Tomorrow is the deadline to submit nominations for Virginia Bio’s Outstanding Contributions to Biosciences awards. Don’t miss your chance to recognize Virginia’s bioscience leaders. 🗓️ Deadline: Feb 20 🔗 Submit now: bit.ly/4bFjFRp #THRiVE2026

Virginia lawmakers can set a critical precedent to protect patients and innovation by opting to study the federal 340B program to see where it’s working for patients – and where it’s not. Read more about how #340B has run off course in @virginianpilot: bit.ly/4rnWhg6

🚀 Registration for THRiVE 2026 is NOW OPEN! Join VA Bio on April 30 at Capital One in Richmond for Virginia’s largest life sciences conference. Thank you to our sponsors for making THRiVE possible! 🔗bit.ly/4s1RgLb #THRiVE2026 #Biotech #LifeSciences #VirginiaBio

PDABs are often pitched as a win for patients, but the reality is much more complicated. @tigerlilycares CEO Maimah Karmo explains how bills to establish a PDAB in VA could restrict access to timely treatments without proven patient savings. Read more: richmond.com/opinion/column…

MUST READ: CEO John Newby explains how #SB278 would exacerbate existing issues with the federal 340B program, raise costs in the Commonwealth, and hinder continued life sciences growth in @RTDNEWS. Keep reading: bit.ly/45DBeNZ

New statewide polling shows Virginians are skeptical of PDABs. Patients trust doctors—not government boards—to make medical decisions. Lawmakers should reconsider HB483 and SB271. Learn more ⬇️ valueofcarecoalition.org/wp-content/upl…

📣 Save the Date: April 30 THRiVE Returns to RVA Virginia Bio’s largest conference is back, uniting the people, ideas, and innovation shaping the future of life sciences in Virginia. More details coming soon. 👀bit.ly/4s1RgLb #THRiVE2026 #Collaboration #Networking

💰 Virginia life science funding now open Start your LOI before the holidays 🎄 Virginia Catalyst Grant Round 19 offers $200K–$800K in non-dilutive funding to move innovation from lab to launch. 📅 LOIs due Jan 16, 2026 🔗 lnkd.in/efWWJMUb #FundingOpportunity #LabToLaunch

🚨 MedTech Innovator 2026 applications are due Dec 1! Startups gain mentorship, visibility, funding opportunities, and a global network. Apply now: medtechinnovator.org/program/

Medicare patients wait an avg. of 5 years to access breakthrough medical products after FDA approval. @RepMGriffith must fix this by advancing legislation to accelerate coverage for innovative devices & tests. More from CEO John Newby in @CardinalNewsVA: bit.ly/4nFlksx

Congratulations to the Commonwealth’s Governor-Elect @SpanbergerForVA and all our newly elected Virginia lawmakers & officials! We’re ready to work with you to drive the continued growth of our leading biotechnology industry and protect local jobs and opportunities in Virginia.

New in @RTDNEWS ➡️ After another innovative biotech facility broke ground in VA last week, CEO John Newby urges lawmakers to continue prioritizing policies that will protect our booming life sciences industry and the thousands of Virginians it supports: bit.ly/4nkGZWF